BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models
Dana-Farber Cancer Institute · Broad Institute · +5 more institutions
Indexed incrossrefdatacitepubmed
Abstract
No abstract available for this paper.
Citation impact
1,440
total citations
- FWCI
- 32.78
- Percentile
- 100%
- References
- 38
Citations per year
Authors
15- DLD LiCorresponding
Dana-Farber Cancer Institute
- LALauren Ambrogio
Broad Institute, Dana-Farber Cancer Institute
- TSTakeshi Shimamura
Brigham and Women's Hospital, Harvard University, Dana-Farber Cancer Institute
- SKShigeto Kubo
Beth Israel Deaconess Medical Center
- MTMasaya Takahashi
Beth Israel Deaconess Medical Center
Topics & keywords
Topics
Keywords
- Erlotinib
- Cancer research
- Biology
- Lung cancer
- T790M
- Epidermal growth factor receptor
- EGFR inhibitors
- Tyrosine kinase
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.